C12N 2830/40
Being an insulator
Official title: being an insulator
C12N2830/40 (Being an insulator) appears on 85 US grants and 172 published applications in this corpus.
Search patents in C12N- Granted patents
- 85
- Published applications
- 172
- Assignees
- 94
- Inventors
- 264
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 7 |
| 2004 | 2 | 9 |
| 2005 | 1 | 9 |
| 2006 | 2 | 19 |
| 2007 | 1 | 3 |
| 2008 | 2 | 1 |
| 2009 | 6 | 3 |
| 2010 | 0 | 6 |
| 2011 | 2 | 6 |
| 2012 | 0 | 7 |
| 2013 | 5 | 0 |
| 2014 | 2 | 6 |
| 2015 | 7 | 8 |
| 2016 | 2 | 6 |
| 2017 | 6 | 12 |
| 2018 | 5 | 8 |
| 2019 | 5 | 6 |
| 2020 | 4 | 13 |
| 2021 | 2 | 4 |
| 2022 | 6 | 9 |
| 2023 | 6 | 6 |
| 2024 | 6 | 7 |
| 2025 | 3 | 9 |
| 2026 | 8 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method to treat disease using a nucleic acid vector encoding a highly compact multi-input logic gate8 Sep 2026US 12,729,384 B2Eidgenossische Technische Hochschule Zurich
- Genomic insulator element exhibiting enhancer blocking activities in lymphocytes and uses thereof11 Aug 2026US 12,702,720 B2St. Jude Children?S Research Hospital
- Regulatable adeno-associated virus (AAV) vector2 Jun 2026US 12,642,869 B2Georg-August-UniversitäT GöTtingen Stiftung öFfentlichen Rechts, UniversitäTsmedizin
- Globin gene therapy for treating hemoglobinopathies21 Apr 2026US 12,606,848 B2Memorial Sloan Kettering Cancer Center
- Compositions and methods for the treatment of metabolic liver disorders3 Feb 2026US 12,540,335 B2Poseida Therapeutics, Inc.
- Viral Vectors For Treating Neurogenic Detrusor Overactivity3 Sep 2026US 2026/0258426 A1Assistance Publique-Hopitaux de Paris
- Cell-free expression vectors and methods for improved protein production13 Aug 2026US 2026/0234646 A1National Resilience, Inc.
- Compositions and methods for the treatment of metabolic liver disorders30 Jul 2026US 2026/0218236 A1Poseida Therapeutics, Inc.
- Methods and compositions for altering gene expression23 Jul 2026US 2026/0207781 A1Emugen Therapeutics LLC
- Recombinant marek's disease virus and uses thereof2 Jul 2026US 2026/0183386 A1Ceva Sante Animale
Most cited
By later US patents
- DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells61US 5,610,053 AThe United States of America as represented by the Department of Health and Human Services · 1997
- Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors38US 6,395,549 B1Medical College of Georgia Research Institute, Inc. · 2002
- Vectors in avian transgenesis37US 6,730,822 B1AviGenics, Inc. · 2004
- Therapeutic retroviral vectors for gene therapy27US 7,901,671 B2bluebird bio, Inc. · 2011
- Enhanced nucleic acid constructs for eukaryotic gene expression26US 9,428,767 B2Dna2.0, Inc. · 2016